Table 1. Clinical characteristics of patients and clinical activity of anti-PD-1 therapy.
| Characteristic | Patients number (%) | CR | PR | SD | PD | ORR (%) | P | DCR (%) | P |
|---|---|---|---|---|---|---|---|---|---|
| Sex | 0.743 | ||||||||
| Male | 31 (55.4) | 0 | 3 | 13 | 15 | 9.7 | 0.813 | 51.6 | |
| Female | 25 (44.6) | 0 | 3 | 11 | 11 | 12.0 | 56.0 | ||
| Histology | 0.506 | ||||||||
| Adenocarcinoma | 52 (92.9) | 0 | 5 | 23 | 24 | 9.6 | 0.116 | 53.9 | |
| Squamous | 3 (5.6) | 0 | 1 | 0 | 2 | 33.3 | 33.3 | ||
| Other | 1 (1.8) | 0 | 0 | 1 | 0 | 0 | 100 | ||
| EGFR mutation type | 0.592 | ||||||||
| Exon 19 deletion | 32 (57.1) | 0 | 3 | 13 | 16 | 9.4 | 0.036 | 50.0 | |
| L858R mutation | 22 (39.3) | 0 | 2 | 10 | 10 | 9.1 | 54.0 | ||
| Exon 18 mutation | 1 (1.8) | 0 | 0 | 1 | 0 | 0 | 100.0 | ||
| Exon 20 insertion | 1 (1.8) | 0 | 1 | 0 | 0 | 100 | 100.0 | ||
| ECOG performance status | 0.014 | ||||||||
| 0 | 11 (19.6) | 0 | 3 | 7 | 1 | 27.3 | 0.207 | 90.9 | |
| 1 | 38 (67.9) | 0 | 3 | 15 | 20 | 7.9 | 47.4 | ||
| 2 | 7 (12.5) | 0 | 0 | 2 | 5 | 0 | 28.6 | ||
| Prior lines of therapy | 0.305 | ||||||||
| 1 | 12 (21.4) | 0 | 3 | 5 | 4 | 25.0 | 0.071 | 66.7 | |
| ≥2 | 44 (78.6) | 0 | 3 | 19 | 22 | 6.8 | 50.0 | ||
| Combined with radiotherapy | 0.189 | ||||||||
| Yes | 8 (14.3) | 0 | 3 | 3 | 2 | 37.6 | 0.008 | 75.0 | |
| No | 48 (85.7) | 0 | 3 | 21 | 24 | 6.3 | 50.0 | ||
| Agents combined with PD-1 antibody | 0.008 | ||||||||
| PD-1 antibody alone | 7 (12.5) | 0 | 0 | 0 | 7 | 0 | 0.091 | 0 | |
| Combined with chemotherapy | 21 (37.5) | 0 | 4 | 11 | 6 | 19.0 | 71.4 | ||
| Combined with bevacizumab | 8 (14.3) | 0 | 2 | 1 | 5 | 25.0 | 37.5 | ||
| Combined with chemotherapy and bevacizumab | 20 (35.7) | 0 | 0 | 12 | 8 | 0 | 60.0 | ||
| Total | 56 | 0 | 6 | 24 | 26 | 10.7 | 53.6 |
PD-1, programmed death-1; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.